- 130 Downloads
Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion. It has proved effective in combination regimens for the eradication of Helicobacter pylori and as monotherapy to heal and relieve symptoms of gastric or duodenal ulcers and gastro-oesophageal reflux. After initial healing, it may be used to prevent recurrence of oesophageal erosions or peptic ulcers in patients in whom H. pylori is not the major cause of ulceration and to reduce basal acid output in patients with Zollinger-Ellison syndrome. Usual dosages are 15 to 60 mg/day, although dosages of ≤ 180 mg/day have been used in patients with hypersecretory states.
In patients with duodenal or gastric ulcer, short term lansoprazole monotherapy was similar to omeprazole and superior to histamine H2 receptor antagonists in achieving healing rates >90%. Lansoprazole was as effective a component of H. pylori eradication regimens as omeprazole, tripotassium dicitrato bismuthate (colloidal bismuth subcitrate) or ranitidine.
Lansoprazole was superior to ranitidine in symptom relief and healing of gastro-oesophageal reflux disease and tended to relieve symptoms more rapidly than omeprazole, although initial healing was similar. As maintenance treatment, lansoprazole was similar to omeprazole and superior to ranitidine in relieving symptoms and preventing relapse. Lansoprazole was also superior to ranitidine in healing and relieving symptoms of oesophageal erosions associated with Barrett’s oesophagus; healing was maintained for a mean of 2.9 years in ≥ 70% of patients. Lansoprazole was also superior to ranitidine in prophylaxis of redilatation of oesophageal strictures.
After ≥ 4 years of use in patients with Zollinger-Ellison syndrome, lansoprazole 60 to 180 mg/day effectively controlled basal acid output. Dosages may be reduced in some patients once healing and symptom relief has been achieved. Preliminary studies of lansoprazole in patients at risk of aspiration pneumonia or stress ulcers show promise. Although studies show lansoprazole is potentially effective in treating gastrointestinal bleeding, future studies should assess patients’ H. pylori status.
Lansoprazole has been well tolerated in clinical trials, with headache, diarrhoea, dizziness and nausea appearing to be the most common adverse effects. Tolerability of lansoprazole does not deteriorate with age and the drug is well tolerated in long term use (≤ 4 years) in patients with Zollinger-Ellison syndrome or reflux disease.
Thus, lansoprazole is an important alternative to omeprazole and H2 receptor antagonists in acid-related disorders. In addition to its efficacy in healing or maintenance treatment, it may provide more effective symptom relief than other comparator agents.
Lansoprazole provides dose-related inhibition of gastric acid secretion via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells, with doses of 30 to 60mg producing similar acid suppression to omeprazole 40mg. Mean 24-hour gastric pH levels are higher when lansoprazole is given in 2 divided doses rather than 1 dose daily. Lansoprazole is 2 to 8 times more potent than omeprazole in inhibitory effects on H. pylori in vitro and is associated with dose-dependent killing of the bacterium.
Orally administered lansoprazole is well absorbed, with peak plasma concentrations (Cmax) linear over the dose range from 15 to 60mg. Sucralfate does reduce and food may reduce absorption of lansoprazole, and lansoprazole may reduce concentrations of theophylline. Both lansoprazole and the 14-hydroxy metabolite of clarithromycin are found in greater concentrations in plasma when administered together with amoxicillin. The drug is hepatically biotransformed and excreted through the bile and kidneys. The elimination half-life is ≈1 hour. Although clearance is reduced in poor metabolisers of S-mephenytoin, elderly patients and those with hepatic cirrhosis or undergoing haemodialysis, dosage adjustments are usually not considered except for patients with severe liver failure. For ease of administration, the enteric-coated granules in lansoprazole capsules may be mixed with apple sauce or juice before administration, with no major changes in pharmacokinetics.
In peptic ulcer healing and symptom relief, lansoprazole 15 to 60 mg/day monotherapy for 4 to 8 weeks was similar or superior in efficacy to omeprazole 20 to 40 mg/day. Lansoprazole 30 mg/day was similar or superior to ranitidine and superior to famotidine in ulcer healing. When used in combination with ≥2 antibacterials, lansoprazole 30 to 60 mg/day was an effective part of regimens capable of achieving eradication of H. pylori in ≥90% of patients, although lansoprazole monotherapy was ineffective. The probability of achieving eradication in ≥90% of patients was highest in regimens incorporating ≥2 antibacterial agents and using ≤4 weeks of lansoprazole 60 mg/day. Healing rates seen in a subset of ≥1300 patients from these H. pylori eradication studies (receiving mono-, dual or triple therapy) were similar to those seen in earlier lansoprazole monotherapy trials. Healing was not affected by the number of agents in the regimen, the lansoprazole dosage or the ability of the regimen to eradicate H. pylori. As part of regimens with ≥2 antibacterial agents, lansoprazole 60 mg/day was as effective as omeprazole 40 mg/day, tripotassium dicitrato bismuthate 120mg 4 times daily or ranitidine 300 mg/day in H. pylori eradication and was similar to omeprazole and tripotassium dicitrato bismuthate but superior to cimetidine in achieving ulcer healing.
As initial treatment of gastro-oesophageal reflux disease (GORD), lansoprazole 15 to 60 mg/day is superior to ranitidine 150mg twice daily in 2-week symptom relief and 4-week healing. Lansoprazole 30 mg/day and famotidine 40 mg/day for 4 weeks achieved similar healing rates, but relapse was more common in patients subsequently maintained on famotidine. No statistically significant differences in GORD healing rates were seen between omeprazole 20 or 40 mg/day and lansoprazole 15 or 30 mg/day, but lansoprazole tended to relieve symptoms more rapidly than omeprazole. Although clear dose-response effects have not been seen in GORD healing across trials, superior symptom relief appears to accompany 30 or 60 mg/day dosages. Following initial GORD healing, lansoprazole 15 and 30 mg/day or omeprazole 20 mg/day for 12 months did not differ in prevention of symptoms or relapse, although both drugs were superior to ranitidine or placebo. Lansoprazole also heals and maintains healing of erosions resistant to H2 receptor antagonists.
Greater rates of endoscopically confirmed healing and relief of symptoms of oesophageal erosions associated with Barrett’s oesophagus were found with lansoprazole 30 to 60 mg/day than with ranitidine 150mg twice daily for 8 weeks. 70% of patients achieved healing and symptom relief during long term (mean 2.9 years) treatment of Barrett’s oesophagus with lansoprazole 60 mg/day. Fewer lansoprazole 30 mg/day than ranitidine 300 mg/day recipients with oesophageal strictures required redilatation during 12 months of treatment, but most of those required the procedure during the first 6 months of treatment.
In patients treated for up to 4 years, lansoprazole 60 to 180 mg/day effectively reduced basal acid output by 95% or to <10 mmol/h and healed ulcers in patients with Zollinger-Ellison syndrome. Preliminary studies of lansoprazole in patients at risk of stress ulcers or of aspiration pneumonia suggest that this treatment has promise; lansoprazole 30mg on the evening before and morning of surgery was similar in efficacy to ranitidine 150mg on the morning of surgery in preventing aspiration pneumonitis. Preliminary results showing that lansoprazole 30 to 60 mg/day can halt or reduce the risk of gastrointestinal bleeding are encouraging for future studies in this indication.
In clinical trials involving >5000 patients receiving lansoprazole 7.5 to 60 mg/day monotherapy or comparators only 2.1 % of lansoprazole recipients withdrew from treatment (vs 2.6% receiving ranitidine, 1.2% on famotidine or 1.6% on omeprazole). The most common adverse events included headache (8.8%), diarrhoea (3.5%), nausea (2.0%), dizziness (1.6%), vomiting (1.4%) and constipation (1.0%). However, when non-drug-related adverse events were excluded, only headache, diarrhoea, dizziness and nausea occurred in >1 % of patients. There was no increase in adverse events in elderly patients, in whom headache (4%), diarrhoea (4.7%), nausea (2.9%), dizziness (2.9%) and constipation (2.9%) were most common. Serious adverse events occurred in only 0.6% of lansoprazole recipients in clinical trials and no patterns occurred to suggest a specific mechanism for these events.
Lansoprazole is generally well tolerated in long term treatment in patients with GORD or Zollinger-Ellison syndrome. No significant differences in the number of adverse events with lansoprazole compared with omeprazole, ranitidine or placebo have been observed in long term studies. Diarrhoea appeared to be the most commonly reported adverse event associated with long term lansoprazole treatment.
In H. pylori eradication regimens in Canada, lansoprazole and omeprazole triple therapies appear less expensive than other triple therapy, dual therapy or H2 receptor antagonist monotherapy regimens. A UK model assessing direct medical costs after lansoprazole, ranitidine or omeprazole therapy reported these 3 agents to be similarly cost effective in peptic ulcer or dyspepsia patients. Lansoprazole, however, was clearly more cost effective than the other 2 agents in the treatment of GORD.
In the US, lansoprazole was shown to be a less costly treatment of GORD than omeprazole, laparoscopic fundoplication surgery or brandname H2 receptor antagonists. However, generic ranitidine or cimetidine were less expensive than lansoprazole in GORD treatment.
In the prevention of GORD relapse, lansoprazole was more cost effective than high dose H2 receptor antagonists and similar to standard doses of H2 receptor antagonists in some patients.
Dosage and Administration
Usual dosages of lansoprazole for use in the treatment of gastric or duodenal ulcer (ulcer healing or H. pylori eradication) or reflux oesophagitis healing are 15 to 60 mg/day for 4 to 8 weeks, with dosages of 15 to 30 mg/day for maintenance treatment, where indicated. The drug is generally administered before meals and is given either once daily in the morning or in divided doses morning and evening. Patients with Zollinger-Ellison syndrome usually receive 60 mg/day initially, with the dose then titrated to reduce basal acid output to <5 or <10 mmol/L. Dosage adjustments may be considered in patients with severe liver disease, but are not required for elderly patients or those with renal insufficiency. The use of lansoprazole in children has not been fully studied.
KeywordsOmeprazole Duodenal Ulcer Ranitidine Lansoprazole Triple Therapy
Unable to display preview. Download preview PDF.
- 5.Blum RA, Vermeire GD, Shi H, et al. Gastric pH levels with lansoprazole 15 mg and 30 mg qd, omeprazole 20 mg qd, and ranitidine 150 mg qid [abstract]. Gastroenterology 1997 Apr; 112(4): A73Google Scholar
- 6.Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15mg and 30mg of lansoprazole and 20mg omeprazole [abstract]. Gastroenterology 1994 Apr; 106 Suppl.: 197Google Scholar
- 10.Blum RA, Hunt RH, Kidd SL, et al. Pharmacodynamics of various doses of lansoprazole [abstract no. 75]. Am J Gastroenterol 1994; 89(9): 1634Google Scholar
- 12.Vogt K, Hahn H. Bactericidal activity of lansoprazole versus omeprazole in vitro [abstract]. Gut 1996; 39 Suppl. 2: 9–10Google Scholar
- 13.Vicari F, Foliguet B, Conroy MC, et al. Comparative in vitro activity of 8 metal salts, lansoprazole and cefotiam against clinical isolates of H. pylori [abstract]. Gastroenterology 1995; 108(4) Suppl.: A936Google Scholar
- 14.Figura N, Crabtree JE, Datillo M. In-vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother 1997; 39: 589–90Google Scholar
- 15.Tateno M, Nakamura N. Phase I study of lansoprazole (AG-1749) antiulcer agent: capsule form. Rinsho Iyaku 1991; 7(1): 51–62Google Scholar
- 19.Sohn D-R, Kwon J-T, Kim H-K. Influence of S-mephenytoin phenotype on the lansoprazole metabolism [abstract]. Clin Pharmacol Ther 1996 Feb; 59: 137Google Scholar
- 22.Danz-Neeff H, Brunner G. Comparative kinetic studies with the three proton pump inhibitors omeprazole, lansoprazole and pantoprazole in patients with complete liver cirrhosis [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A90Google Scholar
- 23.Siringo S, Bolondi L, Gramantieri L, et al. Pharmacokinetic of lansoprazole in cirrhotics with different degree of liver function derangement [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A221Google Scholar
- 26.Barclay ML, Begg EJ, Robson RA, et al. The pharmacokinetics of lansoprazole in normal volunteers and patients with reflux oesophagitis [abstract]. Clin Exp Pharmacol Physiol 1993 Suppl. 1: 3Google Scholar
- 27.Granneman GR, Karol MD, Locke CS. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monk 1995 Oct; 17: 460–4Google Scholar
- 29.Cavanaugh J, Locke C, Shi H, et al. Assessment of the effect of sucralfate on the bioavailability of lansoprazole and omeprazole [abstract]. Am J Gastroenterol 1995 Sep; 90: 1577Google Scholar
- 30.Bergstrand R, Grind M, Nyberg G, et al. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest 1995 Feb; 9: 67–71Google Scholar
- 31.Brummer R-JM, Geerling BJ, Stockbrügger RW. Acute and chronic effect of lansoprazole and omeprazole in relation to food intake [abstract no. T127]. Gut 1995; 37 Suppl. 2: A32Google Scholar
- 32.Mainz D, Borner K, Koeppe P, et al. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin when given single and concomitant [abstract no. 3066]. Presented at the 20th International Congress of Chemotherapy; 1997 Jun–Jul; SydneyGoogle Scholar
- 33.St Peter JV, Awni WM, Granneman GR, et al. The effects of lansoprazole on the disposition of antipyrine and indocyanine green in normal human subjects. Am J Ther 1995 Aug; 2: 561–8Google Scholar
- 35.Cavanaugh JH, Schneck DW, Mukherji D, et al. Lansoprazole does not alter the pharmacokinetics nor chronotropic effect of single dose propanolol [abstract]. 10th World Congress on Gastroenterology; 1994: Abstracts II: 654PGoogle Scholar
- 36.Karol MD, Mukherji D, Cavanaugh JH. Concomitant multi-dose lansoprazole does not alter single-dose phenytoin pharmacokinetics in subjects [abstract]. 10th World Congress on Gastroenterology 1994; Abstracts II: 654PGoogle Scholar
- 37.Karol MD, Mayersohn M, Eason CJ, et al. Evaluation of interaction potential between lansoprazole and clarithromycin (Biaxin Rm) in normal subjects [abstract]. Am J Gastroenterol 1995 Sep; 90: 1583Google Scholar
- 39.Girre C, Coutelle C, David P, et al. Lack of effect of lansoprazole on the pharmacokinetics of ethanol in male volunteers [abstract]. Gastroenterology 1994 Apr; 106 Suppl.: A504Google Scholar
- 41.TAP Holdings Inc. Data on file.Google Scholar
- 47.Iwasaki A, Uno A, Okano N, et al. Helicobacter pylori eradication method for peptic ulcers — comparison of lansoprazole plus single- and double-antibacterial agent treatment regimens [abstract no. API 48]. 10th Asian-Pacific Congress on Gastroenterology 1996 Sep 19: 211Google Scholar
- 50.Dobrilla G, Italian Duodenal Ulcer Group for the study of Lansoprazole. Lansoprazole vs omeprazole in healing and relapse prevention of duodenal ulcer [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A96Google Scholar
- 51.Florent C, Audigier JC, Boyer J, et al. Efficacy and safety of lansoprazole in the treatment of gastric ulcer: a multicentre study. Eur J Gastroenterol Hepatol 1994; 6: 1135–9Google Scholar
- 53.Bardhan KD, Crowe J, Thompson RPH, et al. Lansoprazole v ranitidine maintenance treatment for prevention of duodenal ulcer relapse [abstract]. Gastroenterology 1996; 110(4) Suppl.: A56Google Scholar
- 57.Russo A, Dattilo M. Bedtime administration of lansoprazole does not alter its superior efficacy versus ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. Wyeth S.p.A., Aprilia, Italy. 1997. (Data on file)Google Scholar
- 60.Harlet L, Penson J, Boesaart E, et al. Lansoprazole in maintenance therapy for resistant duodenal ulcers [abstract no. 1392]. Gut 1995; 37 Suppl. 2: A163Google Scholar
- 61.Lanza F, Goff J, Silvers D, et al. Lansoprazole for one year prevents recurrence of duodenal ulcer [abstract]. 10th World Congress on Gastroenterology 1994; Abstracts II: 27PGoogle Scholar
- 62.Kovacs TOG, Campbell DR, Richter JE, et al. Lansoprazole (LAN) is safe and effective for one year in preventing recurrence of duodenal ulcer (DU) disease [abstract]. Am J Gastroenterol 1995; 90(9): 1584Google Scholar
- 63.Campbell DR, Kovacs TOG, Sontag SJ. Lansoprazole (LAN) is safe and effective for one year in preventing recurrence of gastric ulcer (GU) disease [abstract no. 95]. Am J Gastroenterol 1995; 90(9): 1577Google Scholar
- 64.Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. The Mach 1 study: optimal one-week treatment for H. pylori defined? [abstract]. Gut 1995; 37 Suppl. 1: A4Google Scholar
- 65.Digestive Health InitiativeSM of the American Digestive Health FoundationSM. The report of the Digestive Health InitiativeSM International Update Conference on Helicobacter pylori. Presented at Digestive Disease Week; 1997 May 14: Washington, DCGoogle Scholar
- 66.Chey WD, Fey D, Scheiman JM, et al. The role of acid suppression in the effects of lansoprazole and ranitidine on the 14C-urea breath test [abstract]. Gastroenterology 1996; 110(4) Suppl.: A80Google Scholar
- 68.Eberl T, Barnert J, Wagner T, et al. Combination therapy with lansoprazole and roxithromycin in Helicobacter pylori eradication [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A100Google Scholar
- 69.Fernandez JA, Suarez A, Aponte L. Dual therapy with azithromycin and lansoprazole for the treatment of duodenal ulcers associated with Helicobacter pylori [abstract no. 295]. Am J Gastroenterol 1996 Sep; 91: 1959Google Scholar
- 70.Medina N, Reymunde A. Helicobacter pylori eradication with clarithromycin and lanzoprazole in short term period (14 days) [abstract no. 148]. Am J Gastroenterol 1996; 91(9): 1920Google Scholar
- 71.Sierra F, Gutierrez O, Molano B, et al. Eradication of Helicobacter pylori with lansoprazole and clarithromycin [abstract]. Gastroenterology 1995; 108(4) Suppl.: A219Google Scholar
- 73.Chahin NJ, Rigo GP, Perini M, et al. Short triple therapy for Helicobacter pylori (HP) eradication in duodenal ulcer (DU) patients: could it be even shorter? [abstract]. Gastroenterology 1996; 110(4) Suppl.: A78Google Scholar
- 75.Sierra F, Otero W, Gutierrez O, et al. One week full-dose triple therapy: new standard for Helicobacter pylori treatment in Latin America [abstract]. Gastroenterology 1996; 110(4) Suppl.: A258Google Scholar
- 76.Egawa S, Suzaki Y, Murakawa Y, et al. A comparative study of the early and late combined therapy with lansoprazole and amoxicillin in patients with H. pylori-positive peptic ulcer [in Japanese]. Shinyaku to Rinsho 1996 Feb; 45: 390–6Google Scholar
- 79.Katoh M, Asaka M, Kudoh M, et al. Clinical efficacy of lansoprazole in eradication of Helicobacter pylori. J Clin Gastroenterol 1995; 20 Suppl. 2: SI12–4Google Scholar
- 81.Louw JA, van Rensburg C, Moola S, et al. One versus two weeks single dose lansoprazole based combination therapy: efficacy of H. pylori eradication and duodenal ulcer healing [poster no. 4]. S Afr Med J 1996; 86(9): 1122Google Scholar
- 86.Tsai T-C, Lin H-H, Huang L-C, et al. Lansoprazole-containing triple therapy on Helicobacter pylori associated gastric ulcers. Tzu Chi Med J 1996; 8(3): 191–6Google Scholar
- 87.Saggioro A, GISU (Interdisciplinary Group for Ulcer Study). A one-week triple therapy vs a two-week dual therapy for eradication and healing of H. pylori (Hp) positive duodenal ulcers (DU): results from a randomized, double blind clinical trial [abstract no. 2208]. Digestive Disease Week; 1997 May 10–16: Washington, DCGoogle Scholar
- 88.Rehmann I, Kadus W. Low-dose lansoprazole short-term triple regimen for eradication of H. pylori [abstract]. Gastroenterology 1997 Apr; 112(4): A38Google Scholar
- 90.Lamouliatte H, Florent C, Vicari F, et al. Effect of lansoprazole and amoxicillin plus metronidazole on the eradication of Helicobacter pylori: a randomized, double blind, multicenter study [abstract]. Gastroenterology 1996; 110(4) Suppl.: A170Google Scholar
- 93.Yonei Y, Tsukada N, Inagaki Y, et al. Effect of lansoprazole/ sucralfate and clarithromycin on Helicobacter pylori infection and recurrence in the patients with peptic ulcer [in Japanese]. Shinyaku to Rinsho 1996; 45(7): 1385–404Google Scholar
- 95.Matsukura N, Onda M, Shirakawa T, et al. High eradication rate of Helicobacter pylori with lansoprazole + amoxicillin + ecabet sodium: new triple therapy with novel mucosal protective agent for the treatment of peptic ulcer [abstract]. Gastroenterology 1996; 110(4) Suppl.: A190Google Scholar
- 97.Saita H, Murakami M, Dekigai H, et al. Efficacy of two weeks combination therapy with lansoprazole and amoxillin to eradicate H. pylori [abstract]. 10th World Congress on Gastroenterology 1994; Abstracts II: 74PGoogle Scholar
- 98.Schwartz H, Krause R, Sahba B. Triple vs. dual therapy with lansoprazole, clarithromycin and/or amoxicillin in the eradication of Helicobacter pylori [abstract no. 641], Am J Gastroenterol 1996; 91(9): 2047Google Scholar
- 99.Schwartz H, Krause R, Sahba B. Triple vs. dual therapy with lansoprazole (L), clarithromycin (C), and/or amoxicillin (A) in the eradication of Helicobacter pylori [abstract no. 641]. Am J Gastroenterol 1997 Sep; 91(9): 2047Google Scholar
- 102.Chey WD, Fisher L, Elta GH, et al. One week, bid therapy for H. pylori: a randomized comparison of 2 strategies [abstract]. Gastroenterology 1997 Apr; 112(4): A87Google Scholar
- 103.Bolin TD, Korman MG, Engelman JL, et al. Lansoprazole and bismuth triple therapy in the eradication of Helicobacter pylori [abstract]. Gastroenterology 1997 Apr; 112(4): A76Google Scholar
- 104.Saita H, Murakami M, Dekigai H, et al. Two weeks combination therapy with lansoprazole and amoxicillin for eradication of H. pylori [abstract]. Gastroenterology 1994; 106(4) Suppl.: A171Google Scholar
- 105.Vakil N, Peutz T. Helicobacter pylori eradication treatment with dual therapy (lansoprazole and clarithromycin) in an office-based study [abstract]. 3rd International Congress on the Macrolides Azalides and Streptogramins 1996 Jan: 148–9Google Scholar
- 106.Barbezat G, Schlup M, Lubcke R, et al. Lansoprazole, tetracycline and metronidazole — an effective Helicobacter pylori eradication regime [abstract]. J Gastroenterol Hepatol 1995; 10 Suppl. 2: A47Google Scholar
- 107.Burette A, Lamy V, Ramdani B, et al. Lansoprazole (30 mg OD vs BID) with amoxicillin and clarithromycin to cure Helicobacter pylori infection [abstract]. Gut 1996; 39 Suppl. 2: 33Google Scholar
- 108.Cayla R, Zerbib F, de Mascarel A, et al. High dose of lansoprazole in combination with amoxicillin and clarithromycin twice daily for H. pylori eradication: results of a pilot study [abstract]. Am J Gastroenterol 1994 Aug; 89: 1367Google Scholar
- 112.Isomoto H, Matsunaga K, Ofukuji M, et al. Effect of lansoprazole and clarithromycin plus metronidazole on eradication of Helicobacter pylori [abstract no. API24]. 10th Asian-Pacific Congress on Gastroenterology 1996 Sep 19: 199Google Scholar
- 113.Kodama M, Tsukada H, Fukuda K, et al. Comparative study of successful and unsuccessful cases of Helicobacter pylori eradication [abstract no. AP141]. 10th Asian-Pacific Congress on Gastroenterology 1996 Sep 19: 208Google Scholar
- 114.Kumar N, Shanker A. Study of new short term triple therapy in Helicobacter pylori associated antral gastritis [abstract no. APV24]. 10th Asian-Pacific Congress on Gastroenterology 1996 Sep 19: 121Google Scholar
- 115.Lamouliatte H, Courrier A, Mion F, et al. Triple therapy with roxithromycin-amoxicillin and lansoprazole for Helicobacter pylori eradication: results of an open multicentre study [abstract]. Gastroenterology 1996 Apr; 110 Suppl. A: A171Google Scholar
- 116.Nakata H, Imoto K, Kasamatsu T, et al. Effect of lansoprazole and clarithromycin plus polaprezinc on the eradication of Helicobacter pylori [abstract]. 10th Asian-Pacific Congress on Gastroenterology 1996 Sep 19: 202Google Scholar
- 118.Pryce DI, Harris AW, Gabe SM, et al. One week of lansoprazole, clarithromycin and metronidazole eradicates Helicobacter pylori [abstract]. Gastroenterology 1996; 110(4) Suppl.: A235Google Scholar
- 119.Salomaa A, Kosunen TU, Rautelin H, et al. Screening and eradication of H. pylori infection in adult population of Vammala, Finland [abstract no. 3A:08]. Gut 1996; 39 Suppl. 2: A22–23Google Scholar
- 120.Takahara N, Nakata H, Tanaka T, et al. Effect of lansoprazole and clarithromycin plus amoxicillin on the eradication of Helicobacter pylori [abstract no. API 29]. 10th Asian-Pacific Congress on Gastroenterology 1996 Sep 19: 202Google Scholar
- 124.Nakata H, Imoto K, Kasamatsu T, et al. Eradication of Helicobacter pylori with a combination of lansoprazole, amoxicillin, clarithromycin and polaprezinc [abstract no. API31]. 10th Asian-Pacific Congress on Gastroenterology 1996 Sep 19: 203Google Scholar
- 125.Bateson MC, Diffey BL. New treatments for duodenal ulcer [abstract]. Gastroenterology 1996; 110(4) Suppl.: A59Google Scholar
- 127.Cayla R, de Mascarel A, Zerbib F, et al. High dose of lansoprazole plus amoxicillin versus high dose of lansoprazole plus amoxicillin and clarithromycin for Helicobacter pylori (H. pylori) infection [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A68Google Scholar
- 128.Chey WD, Fisher L, Elta GH, et al. One week, bid therapy for H. pylori: a randomized comparison of 2 strategies [abstract no. 98]. Am J Gastroenterol 1996 Sep; 91: 1906Google Scholar
- 129.De Korwin JD, Joubert M, Bazin N, et al. Lansoprazole versus lansoprazole plus antibiotics in the treatment of Helicobacter pylori gastric infection: a randomised multicenter trial [in French]. Ann Med Nancy Est 1994; 33(2): 123–5Google Scholar
- 132.Catalano F, Privitera U, Branciforte G, et al. Omeprazole vs two different doses of lansoprazole in triple therapy on H. pylori positive duodenal ulcer [abstract no. 4A:08]. Gut 1996; 39 Suppl. 2: A32Google Scholar
- 133.Daskalopoulos G, Lian JX, Ho YY. Randomized controlled study comparing triple therapy containing a proton pump inhibitor to standard triple therapy for the eradication of H. pylori [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A79Google Scholar
- 134.Deltenre M, Jonas C, Burette A, et al. Bazzoli-like schemes are not optimal treatment for HP eradication in Brussels, Belgium [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A93Google Scholar
- 135.Ho AS, Lee SC, Hsu CT. What’s the clinically favored triple therapy? [abstract no. 4A:09]. Gut 1996; 39 Suppl. 2: A32–3Google Scholar
- 136.Jonas C, DeReuck M, Otero J, et al. Low-dose, one-week triple therapies for HP: a randomized study [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A145Google Scholar
- 137.Kihira K, Kimura K, Satoh K, et al. Effect of 1-week triple therapy for Helicobacter pylori infection with lansoprazole or ranitidine and clarithromycin and metronidazole [abstract]. Gastroenterology 1996 Apr; 110 Suppl. A: A154Google Scholar
- 138.Liu WZ, Xiao SD, Xu WW, et al. Efficacy of one-week triple therapy with clarithromycin, furazolidone plus lansoprazole or colloidal bismuth subcitrate for eradication of Helicobacter pylori [abstract no. 4A:10]. Gut 1996; 39 Suppl. 2: A33Google Scholar
- 139.Misiewicz JJ, Harris AW, Bardhan KD, et al. One week low-dose triple therapy for eradication of H. pylori: a large multi-centre, randomised trial [abstract no. W4]. Gut 1996; 38 Suppl. 1: A1Google Scholar
- 140.Müllhaupt B, Flückiger T, Fröhli P, et al. One week low dose triple therapies with lansoprazole or omeprazole are equally effective for H. pylori eradication and ulcer healing [abstract]. Gastroenterology 1996; 110(4) Suppl.: A202Google Scholar
- 142.Spinzi GC, Colombo E, Bortoli A, et al. Lansoprazole vs omeprazole: one week triple therapy in peptic ulcer (preliminary results) [abstract]. Gastroenterology 1997 Apr; 112(4): A298Google Scholar
- 143.Yang JC, Yang CK, Wang JT, et al. Use of lansoprazole with and without antibiotics in the healing of duodenal ulcer and eradication of Helicobacter pylori [abstract no. 1988]. Gut 1995; 37 Suppl. 2: A232–3Google Scholar
- 145.Benhaim MC, Evereux M, Salducci J, et al. Lansoprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial [abstract]. Gastroenterology 1990; 98: A20Google Scholar
- 146.Jansen JBMJ, Hazenberg BP, Tan TG, et al. Lansoprazole (30 mg) is more effective than high-dose ranitidine (2 × 300 mg) in moderate to severe reflux esophagitis — a Dutch multi-center trial [abstract]. Gastroenterology 1996; 110 Suppl.: 143Google Scholar
- 147.Plein K, Stolte M, Fuchs W, et al. Lansoprazole vs. ranitidine — efficacy in healing acute reflux esophagitis and influence on hyperregenerative esophagopathy [abstract]. Gut 1995; 37 Suppl. 2: A38Google Scholar
- 150.Corallo J, Vicari F, Forestier S, et al. Lansoprazole in acute treatment of reflux esophagitis [abstract]. Gastroenterology 1993; 28: A58Google Scholar
- 154.Sekiguchi T, Horikoshi T, Nishioka T, et al. Clinical effect of proton pump inhibitors on reflux esophagitis [in Japanese]. Nip Rinsho 1992 Jan; 50: 131–7Google Scholar
- 155.Rampai P, Courrier A, Lemerez M, et al. Efficacy and safety of lansoprazole 30 mg versus omeprazole for 21 days treatment of acute esophagitis [abstract]. Gastroenterology 1995; 108 Suppl.: A200Google Scholar
- 158.Dorsch E, Jones J, Rose P, et al. Lansoprazole provides superior symptom relief for patients with non-erosive reflux esophagitis [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A98Google Scholar
- 160.Poynard T, Staub JL, Lemerez M, et al. Efficacy and safety of lansoprazole 15 mg OAD or 30mg OAD as one year maintenance treatment for erosive reflux esophagitis: a randomized trial [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A195Google Scholar
- 163.Baldi F, Bardhan KD, Borman BC, et al. Lansoprazole maintains healing in patients with reflux esophagitis [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A55Google Scholar
- 164.Carling L, Axelsson C, Forsell H, et al. Lansoprazole versus omeprazole in long term maintenance treatment of reflux oesophagitis: a Scandinavian multicentre trial [abstract no. 1036] [abstract]. Gut 1996; 39 Suppl. 3: 182Google Scholar
- 172.Pospari D, Forestier S, Vissuzaine CH, et al. Long-term lansoprazole (LAN) treatment in patients with Zollinger-Ellison syndrome (ZES) [abstract]. 10th World Congress on Gastroenterology 1994; Abstracts II: 25PGoogle Scholar
- 178.Nishioka S, Ogoshi K, Ogawa N. Clinical study of lansoprazole (AG-1749) injection on upper gastrointestinal bleeding: hemostatic effect of lansoprazole injection and preventive effect of lansoprazole capsules on re-bleeding [in Japanese]. Rinsho Iyaku 1996; 12(13): 2927–52Google Scholar
- 179.Cole AT, Maclntyre AS, Hawkey GM, et al. Lansoprazole and tranexamic acid alone and in combination for upper gastrointestinal bleeding [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A74Google Scholar
- 181.Colin-Jones DG. Safety of lansoprazole. Br J Clin Pract 1994 May–Jun Suppl. 75: 58-66Google Scholar
- 182.TAP Pharmaceuticals Inc. PrevacidR (lansoprazole) delayed release capsules. In: Physicians’ Desk Reference. Montvale: Medical Economics, 1996: 2562–4Google Scholar
- 183.Penson J, Puttemans M, Fourie E. Safety of lansoprazole in maintenance therapy for reflux oesophagitis [abstract]. Gut 1995; 37 Suppl. 2: A163Google Scholar
- 185.Jones RH, Bosanquet N, Johnson NJ, et al. Cost-effective management strategies for acid-peptic disorders. Br J Med Econ 1994; 7: 99–114Google Scholar
- 186.Sadowski DC, Chiba N, Manzi P. An economic comparison of Helicobacter pylori treatment regimens in Canada [abstract]. Gastroenterology 1997 Apr; 112(4): A274Google Scholar
- 187.Heudebert GR, Wilcox CM, Marks R. Impact of lansoprazole in the management of gastroesophageal reflux disease (GERD)): a cost-utility analysis [abstract]. Am J Gastroenterol 1996 Sep; 91: 1889Google Scholar
- 188.Zagari M, Villa KF, Freston JW. Proton pump inhibitors versus H2-receptor antagonists for the treatment of erosive gastroesophageal reflux disease: a cost-comparative study. Am J Managed Care 1995 Nov-Dec; 1: 247–55Google Scholar
- 189.Harris RA, Kupperman M, Richter JE. The cost effectiveness of proton pump inhibitors vs histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis [abstract]. Presented at the 18th Annual Scientific Meeting of the Society for Medical Decision Making (SMDM). 13–16 October 1996, Toronto, Canada.Google Scholar
- 191.Bardhan KD. Management issues and economic implications in erosive oesophagitis — a case-illustrated discussion. Eur J Clin Res 1997; 9: 85–9Google Scholar
- 196.Anonymous. Release of new European H. pylori eradication guidelines. Inpharma 1996 Nov 9; 1062: 2Google Scholar
- 199.Agence Nationale pour le Développement de l’Évaluation Médicale. Anti-ulcer agents: recommendations and medical references [in French]. Gastroenterol Clin Biol 1996; 20: 991–1008Google Scholar
- 204.Best regimens for H pylori eradication. Scrip 1997 Jun 17(2241): 21Google Scholar